ArticleBiomolecules2023
Lipidomics Profiling and Risk of Coronary Artery Disease in the BioHEART-CT Discovery Cohort.
Article in Biomolecules, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 12 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
12 citing papers in PubMed.
- Trial
- Integration of lipidomic and polygenic risk scores within contemporary clinical cardiovascular risk assessment pathways: a multi-cohort development and validation study.EClinicalMedicine · 2026Article
- Screening for high coronary plaque volume in primary prevention: integration of multi-omics and coronary calcium scoring into cardiovascular risk assessment.American journal of preventive cardiology · 2026Article
- Coronary Microvascular Dysfunction and Lipid Molecules: Pathophysiological Mechanisms, Clinical Assessment, and Therapeutic Implications.Journal of personalized medicine · 2026Review
- Review
- A Systemic Perspective of the Link Between Microbiota and Cardiac Health: A Literature Review.Life (Basel, Switzerland) · 2025Review
- Beyond Cholesterol: Unraveling Residual Lipidomic Risk in Cardiovascular Health.Current atherosclerosis reports · 2025Review
- Transforming Cardiovascular Risk Prediction: A Review of Machine Learning and Artificial Intelligence Innovations.Life (Basel, Switzerland) · 2025Review
- Vascular Cytokines and Atherosclerosis: Differential Serum Levels of TRAIL, IL-18, and OPG in Obstructive Coronary Artery Disease.Biomolecules · 2024Article
- Construction and optimization of multi-platform precision pathways for precision medicine.Scientific reports · 2024Article
- Volatilome: A Novel Tool for Risk Scoring in Ischemic Heart Disease.Current cardiology reviews · 2024Review
- Volatilome is Inflammasome- and Lipidome-dependent in Ischemic Heart Disease.Current cardiology reviews · 2024Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
16 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The current coronary artery disease (CAD) risk scores for predicting future cardiovascular events rely on well-recognized traditional cardiovascular risk factors derived from a population level but often fail individuals, with up to 25% of first-time heart attack patients having no risk factors. Non-invasive imaging technology can directly measure coronary artery plaque burden. With an advanced lipidomic measurement methodology, for the first time, we aim to identify lipidomic biomarkers to enable intervention before cardiovascular events. With 994 participants from BioHEART-CT Discovery Cohort, we collected clinical data and performed high-performance liquid chromatography with mass spectrometry to determine concentrations of 683 plasma lipid species. Statin-naive participants were selected based on subclinical CAD (sCAD) categories as the analytical cohort (
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.